title: Discordance: can we capitalize on it to better personalize atherosclerosis treatment?
authors: Center for Prevention and Wellness Research, Baptist Health Medical Group, Miami Beach, FL, USA. KhurramN@baptisthealth.net
authors: Khurram
authors: K
authors: Nasir
authors: Seth S
authors: SS
authors: Martin
authors: Salim
authors: S
authors: Virani
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D016632:Apolipoprotein A-I / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood*; D050197:Atherosclerosis / Q000188:drug therapy* / Q000208:ethnology*; D008078:Cholesterol, LDL / Q000097:blood*; D003324:Coronary Artery Disease / Q000378:metabolism*; D005006:Ethnicity / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D061205:Vascular Calcification / Q000378:metabolism*
chemical_list: D000924:Anticholesteremic Agents; D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008078:Cholesterol, LDL; D017270:Lipoprotein(a)
keywords: Coronary artery calcium; Lipids; Risk; Subclinical atherosclerosis